ImmunityBio releases early brain cancer treatment trial data; shares down
ReutersJan 23, 2026 1:27 PM
Shares of drug developer ImmunityBio IBRX.O fall 3% to $7.13 premarket
Co says 19 of 23 patients in its ongoing study for recurrent glioblastoma, an aggressive brain cancer, remain alive after treatment, with median survival not yet reached
Co says its experimental chemo-free combo of Anktiva and CAR‑NK cells aims to help the immune system fight the tumor
Anktiva is an immune‑activating protein and part of a chemo‑free combo being tested in recurrent glioblastoma
Patients showed improved immune cell counts after one treatment cycle - IBRX
IBRX fell ~23% in 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
National Debt Bomb Ignited? Musk Warns U.S. Will Be 1000% Bankrupt Without AI
TradingKey - Tesla (TSLA) CEO Elon Musk recently issued another warning regarding the rapidly ballooning U.S. national debt. He stated clearly that without artificial intelligence and robotics, the United States will inevitably head toward fiscal bankruptcy.TradingKey
11 hours ago
Tesla Stock Outlook: Competing With Rivian, Robotaxi Potential, and 2026 Prospects
There is much conversation about the prospect of investing in Tesla (TSLA) as we move closer to 2026. The volatility of its share price in 2025 is leading many investors to consider if they should purchase shares of Tesla given the alternatives available in terms of electric vehicles (Rivian, etc.).TradingKey
11 hours ago
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 marketTradingKey
Wed, Feb 4
